Buscar
Mostrando ítems 1-2 de 2
Artículo
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
(Nature Research, 2021-12-01)
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an ...
Artículo
Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy
(MDPI, 2022)
Targeted therapy in metastatic melanoma often achieves a major tumour regression response and significant long-term survival via the release of antigens that reinduce immunocompetence. The biomarkers thus activated may ...